Patients with multiple myeloma who achieve minimal residual disease (MRD) negativity have been shown to have better outcomes compared with MRD positive patients¹

Achieving deeper responses can improve outcomes²

Sustained MRD– = MRD– for 1 year

MRD is the low level of malignant cells that persist even after a complete response with myeloma treatment¹

The methods used for determining MRD negativity include:

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive^6,7

Meta-analysis of 43 studies involving 8,114 patients:

Meta-analysis of 22 studies involving 4,462 patients:

MRD negativity is being considered as a regulatory surrogate endpoint for PFS^8,9

Abbreviations

IMWG, International Myeloma Working Group; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival.

References

Kumar SK, et al. Lancet Oncol 2016;17:e328–46;
Paiva B, et al. Blood 2015;125:3059–68;
Durie BGM, et al. Cancer 1975;36:842–54;
Flores-Montero J, et al. Leukemia 2017;31:2094–103;
Ho C, et al. Semin Hematol 2018;55:13–8;
Munshi NC, et al. JAMA Oncol 2017;3:28–35;
Munshi NC, et al. Presented at ASH 2019; Poster #4742;
Avet-Loiseau H, et al. Clin Lymphoma Myeloma Leuk 2020;20: e30–7;
Landgren O. Semin Hematol 2018;55:1–3;
Food and Drug Administration. Available at: https://www.fda.gov/media/134605/download;
Holstein SA, et al. Biol Blood Marrow Transplant 2020;26:e7–15

Multiple Myeloma: Elderly Patients

Read article

Multiple Myeloma: High Risk Cytogenetics

Read article

Multiple Myeloma: Renal Impairment

Read article

MAT-AE-2300647-V1-Nov-23

Multiple Myeloma: Minimal Residual Disease

The methods used for determining MRD negativity include:

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive^6,7

MRD negativity is being considered as a regulatory surrogate endpoint for PFS^8,9

Multiple Myeloma: Elderly Patients

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: Renal Impairment

You Will Now Be Leaving the Site

Multiple Myeloma: Minimal Residual Disease

The methods used for determining MRD negativity include:

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive6,7

MRD negativity is being considered as a regulatory surrogate endpoint for PFS8,9

Multiple Myeloma: Elderly Patients

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: Renal Impairment

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive^6,7

MRD negativity is being considered as a regulatory surrogate endpoint for PFS^8,9